AR is an inclusion criterion in 22 clinical trials for breast carcinoma, of which 15 are open and 7 are closed. Of the trials that contain AR status and breast carcinoma as inclusion criteria, 2 are phase 1 (2 open), 5 are phase 1/phase 2 (3 open), 14 are phase 2 (9 open), and 1 is phase 3 (1 open) [4].

Bicalutamide has evidence of efficacy in patients with AR mutation in breast carcinoma [4].

AR is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AR status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

Bicalutamide and leuprolide have evidence of efficacy in patients with AR mutation in malignant salivary gland neoplasm [4].

AR is an inclusion criterion in 2 clinical trials for prostate adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain AR status and prostate adenocarcinoma as inclusion criteria, 2 are phase 2 (1 open) [4].

AR is an inclusion criterion in 2 clinical trials for prostate carcinoma, of which 1 is open and 1 is closed. Of the trials that contain AR status and prostate carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

AR is an inclusion criterion in 2 clinical trials for salivary gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AR status and salivary gland carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

AR is an inclusion criterion in 1 clinical trial for adenocarcinoma of unknown primary, of which 1 is open and 0 are closed. Of the trial that contains AR status and adenocarcinoma of unknown primary as inclusion criteria, 1 is phase 2 (1 open) [4].

AR is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains AR status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

AR is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains AR status and clear cell renal cell carcinoma as inclusion criteria, 1 is early phase 1 (0 open) [4].

AR is an inclusion criterion in 1 clinical trial for fallopian tube carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AR status and fallopian tube carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AR is an inclusion criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AR status and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AR is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains AR status and malignant solid tumor as inclusion criteria, 1 is phase 2 (0 open) [4].

AR is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AR status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AR is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains AR status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

AR is an inclusion criterion in 1 clinical trial for primary peritoneal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AR status and primary peritoneal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AR is an inclusion criterion in 1 clinical trial for renal pelvis and ureter carcinoma, of which 0 are open and 1 is closed. Of the trial that contains AR status and renal pelvis and ureter carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

AR is an inclusion criterion in 1 clinical trial for salivary duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AR status and salivary duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AR is an inclusion criterion in 1 clinical trial for urethral carcinoma, of which 0 are open and 1 is closed. Of the trial that contains AR status and urethral carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

AR is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 0 are open and 1 is closed. Of the trial that contains AR status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].